Join me in my talk on enhancing phenome wide association studies using UKBiobank data at ESHG 2023. Starting in 5 mins at Lomond auditorium, Scottish Events Campus.
#eshg2023
@airindiain My brother and I have been chasing you for refund since Jan 2021 and we haven't received our refund yet. We have contacted customer care, e-commerce and sent multiple feedback forms. Absolutely shameful! Your status shows refunded but we haven't received any refund 😡
Admirable commitment to service and national development shown by the Tata Group. I welcome their gesture of contributing to PM-CARES. Their contribution will touch the lives of many Indians. I thank @TataCompanies and Shri Ratan Tata Ji. #IndiaFightsCorona
2/5: RNA-seq analysis of 194 primary melanomas from a large multi-centre prospective adjuvant trial (AVAST-M) identified a 121 gene expression signature, "Cam_121", that outperforms published alternative signatures in predicting recurrence and survival.
3/5: Cam_121’s prognostic relevance was validated in (n=177) regional LN samples and in two independent published primary melanoma datasets, and stratifies stage II patients into high/low absolute risk of death within 5 years, with important implications for adjuvant therapies.
4/5: Also, it was observed that primary tumours corresponding to patients in the "high" risk prognostic group had low immune cell representations, confirming (using unbiased approaches) the central prognostic importance of immune cell infiltration in long-term patient outcomes.
5/5: Further prospective clinical trials are warranted to validate Cam_121’s prognostic ability and to examine whether it can be used to better tailor adjuvant therapy for early-stage melanoma patients.
In today's India, the surname of a person does not matter. It is the ability to make one's name that does.
This is an India where corruption is not an option. Competence is the norm.